SHANGHAI YIZHONG(SH:688091) Ge Long Hui A P P·2026-02-02 08:48Core Viewpoint - Shanghai Yizhong (688091.SH) expects significant growth in both revenue and net profit for the fiscal year 2025, driven by the inclusion of its core product, paclitaxel polymer micelles, in the national medical insurance directory [1] Financial Performance - The company anticipates a revenue of 317 million yuan for 2025, representing an increase of 82.72% compared to the previous year [1] - Net profit attributable to the parent company is projected to be 64.132 million yuan, reflecting a growth of 819.42% year-on-year [1] - The net profit after deducting non-recurring gains and losses is expected to reach 60.1208 million yuan, marking a staggering increase of 1,444.75% [1] Product Development - The core product, paclitaxel micelles, has been officially included in the national medical insurance directory in 2025, significantly enhancing market access and patient numbers, which has driven revenue and profit growth [1] - The company is intensifying its R&D efforts, focusing on innovative drugs YXC-001 (a multifunctional monoclonal antibody targeting PD-1, VEGF, and IL-2) and YXC-002 (a fourth-generation small molecule targeted drug), achieving significant breakthroughs in their development [1] - Ongoing Phase III clinical trials for paclitaxel micelles in pancreatic cancer and breast cancer are being conducted steadily [1] R&D Investment - The R&D expenditure for the year is expected to be approximately 85.0603 million yuan, an increase of about 128.63% compared to the previous year [1] - The company is enhancing the management of sales and administrative expenses to ensure reasonable spending and effective control, allowing for substantial profit growth while maintaining R&D investment [1]